Pharmaceutical Sales- Senior Alzheimer's Disease Consultant
This job is no longer available
There are still lots of open positions. Let's find the one that's right for you.
About The Position
At Lilly, we unite caring with discovery to make life better for people around the world. We are a global healthcare leader headquartered in Indianapolis, Indiana. Our employees around the world work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to our communities through philanthropy and volunteerism. We give our best effort to our work, and we put people first. We're looking for people who are determined to make life better for people around the world. Lilly's ongoing research and commercial efforts in Alzheimer's disease (AD) present one of the most exciting opportunities in the history of the company. There is currently a significant, growing, and intense unmet need across all key players. AD is the sixth leading cause of death in the US, and of the top 10 causes of death, it is the only disease with an increasing mortality rate and the only one that cannot be prevented or cured. Lilly's goal is to make the dementia associated with the disease preventable. We are uniquely positioned to achieve this goal: following 30+ years of investment in AD research and development across both therapeutics and diagnostics, Lilly's landmark Trailblazer-Alz 2 Phase 3 clinical trial published in 2023, the beta-amyloid plaque clearing therapy, donanemab, demonstrated a significant slowing of decline in a composite measure of cognition and daily function in patients with early symptomatic AD. With these ground-breaking positive data, donanemab, brand name Kisunla, was granted FDA approval in July 2024 paving the way for Lilly to address this significant unmet need by promoting Kisunla along with an arsenal of AD diagnostics that support the timely and accurate identification of patients who may benefit from the therapy. Advanced diagnostics to confirm Alzheimer's disease pathology are becoming an increasingly critical component of the diagnostic pathway to identify those patients most likely to benefit from therapies like donanemab. Lilly launched Amyvid, the first PET amyloid imaging agent to identify evidence of amyloid pathology in the brains of living patients, in the United States in 2012. In 2020, Tauvid, the first PET tau imaging agent, was approved by the FDA. The combined AD diagnostic and therapeutic ecosystem (referral dynamics, comprehensive diagnostics, treatments, and care management) must be further developed for patients to be diagnosed and treated efficiently and effectively, to support positive customer and patient experiences. This position will be instrumental in supporting the development of the US AD ecosystem, most significantly as it relates to the utilization of, and experience associated with, our Alzheimer's diagnostic and therapeutic portfolio.
